RT001: Phase I/II started

Retrotope began a double-blind, dose-escalation, U.S. Phase I/II trial to compare oral RT001 vs. encapsulated non-deuterated linoleic acid ethyl ester for 28 days in 18 ambulatory patients. Patients w...